BSE filing, NSE: SMSPHARMA. Summary written from the filing by ALFA Finder's alert engine.
SMS Pharmaceuticals Ltd: key numbers
- Share price
- ₹524.90
- Market cap
- ₹4,653 Cr
- Revenue (annual)
- ₹886.9 Cr
- Net profit (annual)
- ₹102.0 Cr
- P/E (TTM)
- 45.4×Sector 41.3×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 1.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SMS Pharmaceuticals Ltd
All →SMS Pharmaceuticals Results Update
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
SMS Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue ₹316 Cr (+30% YoY), EBITDA ₹68 Cr at 21% margin, PAT ₹40 Cr (+57%). Strategy: backward integration, high-value APIs, DMF/CEP filings, ₹280 Cr capex.
SMS Pharmaceuticals Q2 FY27 Results: Net Profit ₹39.9 Cr, Up 57.7% YoY
SMS Pharmaceuticals Ltd reported revenue from operations of ₹316.1 Cr (+30.4% YoY) and net profit of ₹39.9 Cr (+57.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹39.9 Cr · +57.7% YoY
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals received an Income Tax appellate order under Section 250 dismissing its appeal for AY 2018-19. The company says there is no material impact and is reviewing next steps.
- Value
- ₹0.40 Cr
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals disclosed that the CIT(Appeals) dismissed its appeal against a ₹7.19 Crore income tax assessment for AY 2018-19. The company is reviewing the order and expects no material impact.
- Value
- ₹7.19 Cr
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals received an Income Tax appellate order allowing its appeal for AY 2023-24. The outstanding tax demand of Rs.45.63 Crore, including interest, stands vacated.
- Value
- ₹45.63 Cr
Other management change announcements
All →Krishna Institute of Medical Sciences Management Change
KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.
- Execution
- 5 years
Krowniq Management Change
Krowniq Limited appointed Mr. Mahesh Sharma as Company Secretary and Compliance Officer, effective 04-11-2026, following a board meeting on the same day. The filing is a Key Managerial Personnel change disclosure.
One Global Service Provider Management Change
One Global Service Provider appointed Padmakar Pandit as Non-Executive Independent Director for 60 months. Sanjay Upadhyay was re-appointed Executive Director, effective April 22, 2027.
Whirlpool of India Management Change
Whirlpool of India disclosed the resignations of Head-Accounting Prafulla Kandpal and Head-Taxation Vijay Waghmore. Their relieving dates are 30 October and 13 November 2026.
PDS Management Change
PDS Limited disclosed the resignation of Non-Executive Independent Director Bangalore Gangaiah Srinivas, effective November 4, 2026. The resignation cites pre-occupation and personal commitments, with no other material reason.
Arvee Laboratories (India) Management Change
Arvee Laboratories appointed Shalin Chokshi as Executive Director and Duttsagar Chavda as Company Secretary, both effective 3 November 2026. Non-executive director Saurin Gandhi resigned from the Board effective the same date.